
Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa ...
STARt-002 is a Phase 1b/2 clinical study assessing invikafusp alfa in combination with Gilead’s Trodelvy® for HR+/HER2- and TNBC breast cancer patients across leading U.S. and Canadian breast cancer centers CAMBRIDGE, Mass., May 8, 2025 / …